Title: Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951
Authors: Cavé, Hélène ×
Suciu, Stefan
Preudhomme, Claude
Poppe, Bruce
Robert, Alain
Uyttebroeck, Anne
Malet, Michèle
Boutard, Patrick
Benoit, Yves
Mauvieux, Laurent
Lutz, Patrick
Méchinaud, Françoise
Grardel, Nathalie
Mazingue, Francoise
Dupont, Madeleine
Margueritte, Geneviève
Pages, Marie-Pierre
Bertrand, Yves
Plouvier, Emmanuel
Brunie, Ghislaine
Bastard, Christian
Plantaz, Dominique
Vande Velde, Isabel
Hagemeijer, Anne
Speleman, Frank
Lessard, Michel
Otten, Jacques
Vilmer, Etienne
Dastugue, Nicole
Issue Date: Jan-2004
Publisher: W.B. Saunders
Series Title: Blood vol:103 issue:2 pages:442-50
Abstract: In a series of 153 children with T-cell malignancies enrolled in 2 consecutive European Organization for Research and Treatment of Cancer (EORTC) trials, we assessed the HOX11L2 expression and/or the presence of a t(5;14)(q35;q32). Additionally, in 138 of these patients, HOX11 expression and SIL-TAL rearrangement were also assessed. These alterations were mutually exclusive, and their frequency was 23% (n = 35), 7% (n = 10), and 12% (n = 17), respectively. HOX11L2/t(5;14) positivity was more frequent in acute lymphoblastic leukemia (ALL) with cortical T immunophenotype and in children aged between 6 and 9 years. In contrast with previously reported data, patients positive and negative for HOX11L2/t(5;14) were comparable with regard to clinical outcome as well as to the response to a 7-day prephase treatment or to residual disease at completion of induction therapy. The 3-year event-free survival (EFS) rate (+/- SE percentage) for patients positive and negative for HOX11L2/t(5;14) was 75.5% (+/- 8.1%) and 68.3% (+/- 5.0%), respectively; the hazard ratio was 0.84 (95% confidence interval, 0.40-1.80). Patients with HOX11-high expression and those with SIL-TAL fusion had low levels of residual disease at the end of induction and a favorable prognosis: the 3-year EFS rate was 83.3% (+/- 8.5%) and 75.3% (+/- 12.6%), respectively. The results obtained in HOX11L2/t(5;14) patients in this study do not confirm the unfavorable prognosis reported in previous studies.
ISSN: 0006-4971
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Non-KU Leuven Association publications
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science